Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Head And Neck Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dalnicastobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalnicastobart overview
Dalnicastobart (LVGN-7409) is under development for the treatment of solid tumors including lymphomas, non-small cell lung cancer, metastatic head and neck carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer and hypopharyngeal cancer. It is a humanized monoclonal antibody that acts by targeting CD40. It is administered through intravenous and oral route. The drug candidate is developed based on xLinkAb agonistic cross-linked antibody platform.
The drug candidate was under development for the treatment of triple negative breast cancer, gastroesophageal junction cancer, small cell lung cancer and pancreatic ductal adenocarcinoma.
Lyvgen Biopharma overview
Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.
For a complete picture of Dalnicastobart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
